Advances in anti-tumor drugs with new mechanisms of action

Abstract

Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.

References55

[1]	Scott EC, Baines AC, Gong YT, et al. Trends in the approval of cancer therapies by the FDA in the twenty-first century[J].Nat Rev Drug Discov,2023,22(8): 625-640. DOI:10.1038/s41573-023-00723-4. pmid:37344568
[2]	Micalizzi DS, Sequist LV, Haber DA. Deploying blood-based cancer screening[J].Science,2024,383(6681): 368-370. DOI:10.1126/science.adk1213. pmid:38271495
[3]	Bedard PL, Hyman DM, Davids MS, et al. Small molecules, big impact: 20 years of targeted therapy in oncology[J].Lancet,2020,395(10229): 1078-1088. DOI:10.1016/S0140-6736(20)30164-1. pmid:32222192
[4]	Morrison L, Loibl S, Turner NC. The CDK4/6 inhibitor revolu-tion—a game-changing era for breast cancer treatment[J].Nat Rev Clin Oncol,2024,21(2): 89-105. DOI:10.1038/s41571-023-00840-4. pmid:38082107
[5]	Milletti G, Colicchia V, Cecconi F. Cyclers' kinases in cell division: from molecules to cancer therapy[J].Cell Death Differ,2023,30(9): 2035-2052. DOI:10.1038/s41418-023-01196-z.
[6]	Gao JX, Pickett HA. Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies[J].Nat Rev Cancer,2022,22(9): 515-532. DOI:10.1038/s41568-022-00490-1. pmid:35790854
[7]	Davalos V, Esteller M. Cancer epigenetics in clinical practice[J].CA Cancer J Clin,2023,73(4): 376-424. DOI:10.3322/caac.21765.
[8]	Deng XL, Qing Y, Horne D, et al. The roles and implications of RNA m⁶A modification in cancer[J].Nat Rev Clin Oncol,2023,20(8): 507-526. DOI:10.1038/s41571-023-00774-x.
[9]	Fustin JM, Kojima R, Itoh K, et al. Two Ck1δ transcripts regulated by m⁶A methylation code for two antagonistic kinases in the control of the circadian clock[J].Proc Natl Acad Sci U S A,2018,115(23): 5980-5985. DOI:10.1073/pnas.1721371115.
[10]	Vainonen JP, Momeny M, Westermarck J. Druggable cancer phosphatases[J].Sci Transl Med,2021,13(588): eabe2967. DOI:10.1126/scitranslmed.abe2967.
[11]	Carter PJ, Rajpal A. Designing antibodies as therapeutics[J].Cell,2022,185(15): 2789-2805. DOI:10.1016/j.cell.2022.05.029. pmid:35868279
[12]	Galvez-Cancino F, Simpson AP, Costoya C, et al. Fcγ receptors and immunomodulatory antibodies in cancer[J].Nat Rev Cancer,2024,24(1): 51-71. DOI:10.1038/s41568-023-00637-8. pmid:38062252
[13]	Kontermann RE, Brinkmann U. Bispecific antibodies[J].Drug Discov Today,2015,20(7): 838-847. DOI:10.1016/j.drudis.2015.02.008. pmid:25728220
[14]	Weidanz J. Targeting cancer with bispecific antibodies[J].Science,2021,371(6533): 996-997. DOI:10.1126/science.abg5568. pmid:33649167
[15]	Anon. An NK-cell therapy for CD30⁺lymphomas[J].Cancer Discov,2022,12(6): 1401-1402. DOI:10.1158/2159-8290.CD-NB2022-0027.
[16]	Hurvitz SA. Recent progress in antibody-drug conjugate therapy for cancer[J].Nat Cancer,2022,3(12): 1412-1413. DOI:10.1038/s43018-022-00495-7.
[17]	Tarantino P, Carmagnani Pestana R, Corti C, et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies[J].CA Cancer J Clin,2022,72(2): 165-182. DOI:10.3322/caac.21705.
[18]	Tarantino P, Ricciuti B, Pradhan SM, et al. Optimizing the safety of antibody-drug conjugates for patients with solid tumours[J].Nat Rev Clin Oncol,2023,20(8): 558-576. DOI:10.1038/s41571-023-00783-w. pmid:37296177
[19]	Kulkarni JA, Witzigmann D, Thomson SB, et al. The current landscape of nucleic acid therapeutics[J].Nat Nanotechnol,2021,16(6): 630-643. DOI:10.1038/s41565-021-00898-0. pmid:34059811
[20]	Liu C, Shi QQ, Huang XA, et al. mRNA-based cancer therapeutics[J].Nat Rev Cancer,2023,23(8): 526-543. DOI:10.1038/s41568-023-00586-2. pmid:37311817
[21]	Winkle M, El-Daly SM, Fabbri M, et al. Noncoding RNA therapeutics-challenges and potential solutions[J].Nat Rev Drug Discov,2021,20(8): 629-651. DOI:10.1038/s41573-021-00219-z.
[22]	Childs-Disney JL, Yang XY, Gibaut QMR, et al. Targeting RNA structures with small molecules[J].Nat Rev Drug Discov,2022,21(10): 736-762. DOI:10.1038/s41573-022-00521-4. pmid:35941229
[23]	Wang JY, Doudna JA. CRISPR technology: a decade of genome editing is only the beginning[J].Science,2023,379(6629): eadd8643. DOI:10.1126/science.add8643.
[24]	Saxena M, van der Burg SH, Melief CJM, et al. Therapeutic cancer vaccines[J].Nat Rev Cancer,2021,21(6): 360-378. DOI:10.1038/s41568-021-00346-0. pmid:33907315
[25]	Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines[J].Nat Rev Clin Oncol,2021,18(4): 215-229. DOI:10.1038/s41571-020-00460-2. pmid:33473220
[26]	Dolgin E. Personalized cancer vaccines pass first major clinical test[J].Nat Rev Drug Discov,2023,22(8): 607-609. DOI:10.1038/d41573-023-00118-5. pmid:37438497
[27]	Adamik J, Butterfield LH. What's next for cancer vaccines[J].Sci Transl Med,2022,14(670): eabo4632. DOI:10.1126/scitranslmed.abo4632.
[28]	Sellars MC, Wu CJ, Fritsch EF. Cancer vaccines: building a bridge over troubled waters[J].Cell,2022,185(15): 2770-2788. DOI:10.1016/j.cell.2022.06.035. pmid:35835100
[29]	Lang F, Schrörs B, Löwer M, et al. Identification of neoantigens for individualized therapeutic cancer vaccines[J].Nat Rev Drug Discov,2022,21(4): 261-282. DOI:10.1038/s41573-021-00387-y. pmid:35105974
[30]	Irvine DJ, Maus MV, Mooney DJ, et al. The future of engineered immune cell therapies[J].Science,2022,378(6622): 853-858. DOI:10.1126/science.abq6990. pmid:36423279
[31]	Baker DJ, Arany Z, Baur JA, et al. CAR T therapy beyond cancer: the evolution of a living drug[J].Nature,2023,619(7971): 707-715. DOI:10.1038/s41586-023-06243-w.
[32]	Lahimchi MR, Maroufi F, Maali A. Induced pluripotent stem cell-derived chimeric antigen receptor T cells: the intersection of stem cells and immunotherapy[J].Cell Reprogram,2023,25(5): 195-211. DOI:10.1089/cell.2023.0041. pmid:37782910
[33]	Dagher OK, Posey ADJ. Forks in the road for CAR T and CAR NK cell cancer therapies[J].Nat Immunol,2023,24(12): 1994-2007. DOI:10.1038/s41590-023-01659-y. pmid:38012406
[34]	Laskowski TJ, Biederstädt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy[J].Nat Rev Cancer,2022,22(10): 557-575. DOI:10.1038/s41568-022-00491-0. pmid:35879429
[35]	Lasser SA, Ozbay Kurt FG, Arkhypov I, et al. Myeloid-derived suppressor cells in cancer and cancer therapy[J].Nat Rev Clin Oncol,2024,21(2): 147-164. DOI:10.1038/s41571-023-00846-y. pmid:38191922
[36]	Baulu E, Gardet C, Chuvin N, et al. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives[J].Sci Adv,2023,9(7): eadf3700. DOI:10.1126/sciadv.adf3700.
[37]	Reardon S. MEGA-CRISPR tool gives a power boost to cancer-fighting cells[J].Nature,2024,626(8001): 940. DOI:10.1038/d41586-024-00511-z.
[38]	Ornes S. News feature: what's the best way to build a molecular machine?[J].Proc Natl Acad Sci U S A,2018,115(38): 9327-9330. DOI:10.1073/pnas.1811689115.
[39]	Schmidt CK, Medina-Sánchez M, Edmondson RJ, et al. Enginee-ring microrobots for targeted cancer therapies from a medical perspective[J].Nat Commun,2020,11(1): 5618. DOI:10.1038/s41467-020-19322-7.
[40]	Gwisai T, Mirkhani N, Christiansen MG, et al. Magnetic torque-driven living microrobots for increased tumor infiltration[J].Sci Robot,2022,7(71): eabo0665. DOI:10.1126/scirobotics.abo0665.
[41]	Zhang SL, Scott EY, Singh J, et al. The optoelectronic microrobot: a versatile toolbox for micromanipulation[J].Proc Natl Acad Sci U S A,2019,116(30): 14823-14828. DOI:10.1073/pnas.1903406116.
[42]	Ho D. Artificial intelligence in cancer therapy[J].Science,2020,367(6481): 982-983. DOI:10.1126/science.aaz3023. pmid:32108102
[43]	Service RF. Software-designed miniproteins could create new class of drugs[J].Science,2022,376(6588): 17. DOI:10.1126/science.abq2804. pmid:35357932
[44]	Callaway E. AlphaFold found thousands of possible psychedelics. Will its predictions help drug discovery?[J].Nature,2024,626(7997): 14-15. DOI:10.1038/d41586-024-00130-8.
[45]	Lampe GD, King RT, Halpin-Healy TS, et al. Targeted DNA integration in human cells without double-strand breaks using CRISPR-associated transposases[J].Nat Biotechnol,2024,42(1): 87-98. DOI:10.1038/s41587-023-01748-1.
[46]	Tao F, Qi QL. Make more digital twins[J].Nature,2019,573(7775): 490-491. DOI:10.1038/d41586-019-02849-1.
[47]	Mariño KV, Cagnoni AJ, Croci DO, et al. Targeting galectin-driven regulatory circuits in cancer and fibrosis[J].Nat Rev Drug Discov,2023,22(4): 295-316. DOI:10.1038/s41573-023-00636-2.
[48]	Vogel FCE, Chaves-Filho AB, Schulze A. Lipids as mediators of cancer progression and metastasis[J].Nat Cancer,2024,5(1): 16-29. DOI:10.1038/s43018-023-00702-z.
[49]	Stine ZE, Schug ZT, Salvino JM, et al. Targeting cancer metabolism in the era of precision oncology[J].Nat Rev Drug Discov,2022,21(2): 141-162. DOI:10.1038/s41573-021-00339-6.
[50]	Gurbatri CR, Arpaia N, Danino T. Engineering bacteria as interactive cancer therapies[J].Science,2022,378(6622): 858-864. DOI:10.1126/science.add9667. pmid:36423303
[51]	Sajjath SM, Gola A, Fuchs E. Designer bugs as cancer drugs?[J].Science,2023,380(6641): 132-133. DOI:10.1126/science.adh3884. pmid:37053342
[52]	Erdmann J. How gut bacteria could boost cancer treatments[J].Nature,2022,607(7919): 436-439. DOI:10.1038/d41586-022-01959-7.
[53]	Prillaman MK. How cancer hijacks the nervous system to grow and spread[J].Nature,2024,626(7997): 22-24. DOI:10.1038/d41586-024-00240-3.
[54]	da Costa AABA, Chowdhury D, Shapiro GI, et al. Targeting replication stress in cancer therapy[J].Nat Rev Drug Discov,2023,22(1): 38-58. DOI:10.1038/s41573-022-00558-5.
[55]	Pérez-González A, Bévant K, Blanpain C. Cancer cell plasticity during tumor progression, metastasis and response to therapy[J].Nat Cancer,2023,4(8): 1063-1082. DOI:10.1038/s43018-023-00595-y.

Advances in anti-tumor drugs with new mechanisms of action

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References55

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[6]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[12]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[13]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[14]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[15]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.